Discover the COVIRNA session at the EHMA 2021 Annual Conference
The COVIRNA project will be participating at the EHMA 2021 Annual Conference with the session ‘Towards personalised medicine – an innovative diagnostic tool to identify cardiovascular complications in COVID-19 patients’ on Wednesday, 15 September at 13.30 CEST.
EHMA 2021 Annual Conference is organised by the European Health Management Association (EHMA) – one of the COVIRNA project partners – and is the preeminent European conference on health management, bringing together researchers, academia, health managers, policy and decision-makers to exchange knowledge on innovative practices and excellent delivery of healthcare to ensure the health and well-being for Europe’s citizens and communities.
The COVIRNA session will examine the benefits of personalised disease management on health systems and discuss how patient-centred care and personalised medicine can improve disease outcomes and enhance patients’ quality of life. Personalised disease management and personalised medicine move away from a one-size-fits-all solution in favour of an approach that recognises the genomic and clinical specificities of each patient, and the different forms complex diseases can take. Treatments and care planning can therefore be tailored and adapted to the patient to ultimately improve their health outcomes by making treatments more effective and with fewer side effects.
The session will also cover additional questions that are crucial to consider when moving towards personalised medicine. For instance, while the use of personalised medicine often relies on data, multiple challenges arise when it comes to data sharing across health institutions. We will thus discuss potential ways in which these challenges can be addressed. Furthermore, Artificial Intelligence and machine learning have proven to be powerful tools in health and we will highlight how we can employ them to develop predictive models. Lastly, we will explore how we can bring innovations, such as the COVIRNA tool, to the end-users, namely the patients.
COVIRNA will also be at the EHMA Conference with an informative booth, where we will share information on the advancements and latest news about the project. We will be joined by consortium members, as well as members of the project Stakeholder Advisory Board (STAB). EHMA 2021 will be a great opportunity to raise awareness on the COVIRNA diagnostic tool, its innovative approach and its benefits to patients. We will also use the Conference as an opportunity to connect with healthcare professionals and policy and decision-makers to ensure the uptake of our diagnostic tool once on the market.
If you are interested in learning more about the session and attending, please visit www.ehmaconference.org.